Embed Size (px)
Citation preview
Advertising Sales ContactCustomNEWS, Inc. (Jenn Waters, 240/401-6779, [email protected], is the authorized vendor for DIA 2020 Show Daily advertising.
Warning: The Source Group is a not an authorized vendor. Drug Industry News is not associated with DIA in any way and will not be distributed inside the convention center.
What is the DIA Show Daily?For the past 14 years, the DIA Show Daily has been the official daily newspaper of the DIA Global Annual Meet-ing. Attendees turn to this publication for meeting news, updates, and the exhibitor list and floor plan.
Why advertise in the DIA 2020 Global Annual Meeting Official Show Daily?Exhibitors advertising in the meeting’s official show daily reach their target audience at precisely the right time, through both print and digital distribution.
What should I know?• Publication is letter-size, and printed on gloss paper stock• Budget-friendly rates for listings in our Product & Services Showcase.• Save 15% if you reserve your advertising placements by February 28, 2020.
Are there any benefits for advertising in the DIA 2020 Show Daily?Yes! Advertising placements secured in the DIA 2020 Show Daily by April 24, 2020, will earn one Assignment Order Point for each $1,000 spent.
Will the DIA 2020 Show Daily include the exhibitor list and floor plan?Yes, the updated list and floor plan will be in ev-ery issue. DIA 2020 Show Daily advertisers will be bolded in the alphabetical listing.
When and how is the official DIA Show Daily distributed?Our Show Daily distribution team wears green shirts to distinguish our publication as the official show daily. Notifications are sent to remind attendees to look for the green shirts. • Issue 1 (Sunday) is distributed at registration counters at official DIA hotels and also actively distributed at the convention center. • Issues 2, 3 and 4 (Monday – Wednesday) are actively distributed inside and outside of the convention center. • Digital links are included in DIA’s daily email newsletter and shared via other social media.
Can I submit editorial content?Yes, each advertising placement (1/4 page or larger) includes the complimentary publication of one 300-word article/press release, with im-age, in each issue that the ad appears.
Advertise in the DIA 2020 Global Annual Meeting Official Show Daily of the to:• Reach attendees every morning in Washington, DC.• Stand out in the exhibit hall.• Promote products and services.• Publish complimentary press releases (including images).
Stand Out in Washington, DC: Advertise in theDIA 2020 Global Annual Meeting Official Show Daily
DIA 2020 Global Annual Meeting
Official Show Daily
Early Bird Discount!Save 15%, book by February 28, 2020!
SHOW DAILY
9:00am–12:30pm Half Day Morning Preconference Short Courses*
9:00am–5:00pm Full Day Preconference Short Courses*
1:30–5:00pm
Half Day Afternoon Preconference Short Courses*
2:30–5:00pm
Professional Development Sessions
Sunday
Issue OneJune 23, 2019
*Space is limited for Preconference Short Courses. Onsite Registration is available, but not guaranteed.
Welcome to San Diego!
®
IWRS/RTMS|CTMS| Safety|ePRO/eCOA|AE/SAE|Imaging|Reporting
EDC|DM|IWRS|CTMS
Focus on your study,not your bottom line.
Visit Axiom for coffee at #2531. Reach us at www.axiommetrics.com or [email protected].
Fixed cost model. No change orders. Invest to save.
ModuleseClinical Suite
Better Decisions
Short Timelines
Unmatched Service
Unified Technology
Unified eClinical Solution.
Up Close and PersonalGet to know your fellow DIA members with Member Spotlights in each Show Daily. Today’s issue features: • Jonathan Andrus• Stella Blackburn• Linda Bowen• Gerald Dal Pan• Munish Mehra
Professor Gui-do Rasi began his second term as Ex-ecutive Director of the European Medicines Agency (EMA) on Novem-ber 16, 2015. From November 2014 to mid-November 2015, Professor Rasi served as EMA’s Principal Adviser in Charge of Strategy.
From November 2011 to November 2014 he was the Executive Director of EMA and a member of its Management Board in the three years prior.
Dr. Joanne Waldstreicher has oversight across John-son & Johnson pharmaceuti-cals, devices, and consumer products for safety, epide-miology, clin-ical and reg-ulatory operations transformation, collaborations on ethical science, and technology and R&D policies, including those related to clinical trial transpar-ency and compassionate access.
Meet your DIA 2019 Honorary Co-Chairs
Joanne Waldstreicher, MDChief Medical OfficerJohnson & Johnson
Professor Guido Rasi, MDExecutive Director, European Medicines AgencyEuropean Union
Show Daily Bin AdvertisingPlace your advertising graphics on the front and sides of the four DIA Show Daily publication bins placed in the convention center. Cost: $9,500/net. Contact Jenn Waters, [email protected].
Size Width x Depth 1X 2X 3X 4XBellyband* 19” w x 3” h $5,100 per issue, includes printingPage One Strip Ad* 7.25” x 2” n/a n/a n/a $7,500Page One Billboard* 2” x 3.25” n/a n/a n/a $6,700Back Cover* 8.375” x 10.5” n/a n/a n/a $8,500 Inside Front Cover* 8.375” x 10.5” n/a n/a n/a $8,100Inside Back Cover* 8.375” x 10.5” n/a n/a n/a $7,800Full Page 8.375” x 10.5” $2,100 $4,000 $5,700 $7,600 Half Page Vertical 3.5 x 9” $1,800 $3,500 $5,100 $6,600 Half Page Horizontal 7.25 x 4.5” $1,700 $3,300 $4,700 $6,200 1/4 Page 3.5” x 4.5” $800 $1,500 $2,200 $2,900
• Rates Include 4C.• Rates Include one 300-word article/image per ad.• *Early-bird discount not applicable.
SHOW DAILY ADVERTISING NET RATES & SIZES
The DIA Show Daily will feature a Product & Services Showcase, offering the opportunity to highlight products on display at DIA 2020.
• Cost: $650/net per product, appears in all four issues; OR $375/net per product, appears in the Monday and Tuesday Issues.
• Listing includes: company name & booth number; product photo (max. 1.5” w x 2.5” h); 50-word description; and hyperlink in digital version • Organized alphabetically, by company name. • Products introduced after January 1, 2020, will have a “new” symbol next to their listing.
Insertion Order Deadline: May 27, 2020Materials Deadline: June 3, 2020
Product & Services Showcase
Complimentary Editorial/Photo OpportunityEach advertisement (1/4 page or larger) placed in an issue of the DIA Show Daily offers the exhibiting company the opportunity to submit one 300-word press release with color photo or company logo (2.5” w x 2.5” h) for complimentary publication in the same issue the ad appears.
All press releases are due to CustomNEWS, [email protected] by June 3, 2020
Specifications• Sizes – Trim size is 8.375” x 10.5” and is printed on 60# white coated gloss stock.
Bleeds only available for full page ads and spreads across the gutter. Ads should be designed to the sizes indicated, with 3/8” on all sides for bleed ads. Differently-sized ads will be reduced/enlarged to fit the ad size as closely as possible. If provided ads include crop marks, publisher will crop the image accordingly and reduce/enlarge to fit the ad size as needed.
• Files – High-Resolution Adobe PDF files strongly preferred and required for Preview Issue. For printed issues, TIFF, JPEG, EPS accepted. All fonts must be embedded. Files can be e-mailed, sent on a PC-readable CD, or posted to our ftp site (contact us for transfer procedure). All colors should be built out of CMYK process. Files must include high-resolution graphics (300 dpi or better) and all fonts (screen and printer). Color reproduction is assured to generally-accepted industry standards for cold-web newspaper printing.
• Materials – Please send all advertising materials to [email protected]. WeTransfer or Drop Box are the preferred methods for submitting files.
Early Bird Discount: Feb. 28, 2020
Space Reservations: May 27, 2020Ad Materials: June 3, 2020
DIA 2020 Global Annual Meeting Official Show Daily
Early Bird Price:$599/per product
24 • Monday, June 24, 2019 #DIA2019
PRODUCT & SERVICES SHOWCASEPAID ADVERTISEMENTS
AltasciencesBooth #2039
Altasciences is a forward-thinking, mid-size CRO offering a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management.
AMPLEXOR Life SciencesBooth #2431
RIMExpertRIMExpert is an integral part of AMPLEXOR Life Sciences Suite – the only regulated content management and compliance solution for the Life Sciences industry to support the entire product life cycle, from product nomination and development to submission and post-approval maintenance.
BizInt Smart ChartsBooth #937
Boost your competitive intelligence and business development strategy! Used by the top pharma companies for over 20 years, BizInt Smart Charts software helps you create targeted reports and visualizations from the leading drug pipeline and clinical trial databases –including Citeline Trialtrove, ClinicalTrials.gov, and EU Clinical Trials Register.
Protocol First / Clinical Pipe Booth #2736
Clinical Pipe is an EHR-to-EDC connector, used as a productivity tool for clinical research. Instead of manual transcription from EHR-to-EDC, 30-70% of the data flows directly from EHR into the EDC database (e.g., Rave, InForm). This process eliminates transcription errors and SDV, and vastly reduces on-site monitoring visits. Connecting Healthcare
to Clinical Research
EHR-to-EDC. Click. Transfer.
EHR EDC
Exhibitor NewsExhibitor News features press releases submitted by exhibitors at the DIA Global Annual Meeting that advertise in the publication.
With recent advances in technology, computer science and informatics, new techniques in medicine became avail-able, and existing tools and measure-ments were drastically enhanced.
Specifically, in the field of cardiac safety, we saw a change in technology and standard practice. The historical 10 seconds 12-lead ECG has served as the standard for the assessment of drug in-duced ECG effects, but it showed im-portant limitations.
With the introduction of new tech-nologies (biosensors, connected devic-es, implantable devices…), tools allow one to look at longer periods of mon-itoring and allow collecting more data that need to be processed. This will lead to analyzing the ECG recordings as a whole (time changes, beat morphol-
Cardiac Safety: The Promise of Artificial Intelligence (AI)
ogies changes, extraction of abnormal pattern) rather than just assessing a single isolated beat.
Technological enhancements allowed the refinement of tools to the newer ECG monitoring tools, of which we are already in the third-generation. Though artificial intelligence and deep learning are already established in other medical areas like ra-diology, they entered the field of clinical medicine only recently and carefully. This new technology will augment human in-
telligence to improve decision-making, re-sulting in optimal operational processes.
The alliance of technologies and sci-ence will for sure reshape the drug devel-opment process, and the use of contin-uous reading algorithms presents many benefits: improvement of cardiac bio-markers determination, reduction of vari-ability… and will allow a reduction of the number of patients to be enrolled and, as a result, reduction of the cost of the re-search.
Banook Group is actively engage in the innovation pathway by working togeth-er with scientists and clinical researchers on new tools for classification, clustering and analysis of ECG data, with the goal of classifying with more accuracy continu-ous ECG recording. Stop at booth 2104 to share expertise with our team.
Monday, June 24, 2019 • 23#DIA2019
Exhibitor NewsExhibitor News features press releases submitted by exhibitors at the DIA Global Annual Meeting that advertise in the publication.
Program built on FDA’s Sentinel net-work looks to move real-world data re-search to the next level
The Innovation in Medical Evidence Development and Surveillance (IMEDS) program at the Reagan-Udall Founda-tion for the FDA announces plans to in-crease focus on cross-cutting methods research, building on its position as the industry go-to for real-world post-mar-ket safety studies. IMEDS, a transfor-mational public-private partnership, mobilizes data providers, drug manu-facturers, researchers, and the FDA to accelerate research and answer critical patient safety and public health ques-tions.
“Working with our industry partners has made it clear that more research is needed to improve the quality and breadth of real-world data for regu-latory studies,” says Dr. Carla Rodri-guez-Watson, IMEDS’ scientific direc-tor. “For example, there is a need to
gress, the Reagan-Udall Foundation for the FDA is an independent 501(c)3 not-for-profit organization charged with advancing regulatory science to help the FDA accomplish its mission. The Foundation works to improve America’s public health through public-private partnerships that facilitate innovation, foster the use of real-world evidence and identify modern tools and policies to keep pace with today’s rapidly evolv-ing science.
Learn more about the Foundation and its work at www.reaganudall.org.
IMEDS Exploring Cross-Cutting Methods Research in Safety Studiesmap and validate algorithms based on administrative codes for specific clini-cal endpoints – and to improve the ac-curacy of those algorithms.”
Other potential focus areas for IMEDS will include better leveraging machine learning, AI and natural lan-guage processing to identify clinical endpoints, integrate patient reported outcomes, obtain insights from un-structured data, and develop new clus-ter detection methods to provide early detection of potential adverse events or new indications.
In engaging in this research, “IMEDS makes good on FDA’s commitment to Congress and to the public to make tools and resources available to answer real-world safety questions affecting broad patient populations,” says Jac-queline Corrigan-Curay, MD, JD, Direc-tor of the Office of Medical Policy, Cen-ter for Drug Evaluation and Research, FDA.
Created by a nonpartisan act of Con-
In the big data era, extended-wear Holter monitors are greatly enhancing the cardiac safety assessments in clin-ical trials. So, it is important to notice that not all extended-wear Holters (car-diac patch monitors) are the same. eP-atch®, from BioTel Research, provides unique features that maximize patient compliance, setting it apart from all other cardiac patch devices.
Patient compliance for any skin-ad-hered medical device typically falters when perspiration causes the adhesive to fail, or when the patient removes the device because of skin irritation. For most cardiac devices, those situations terminate the recording.
ePatch is different. Its recording sen-sor is easily decoupled from its adhe-sive backing. If the backing has lost ad-hesion it is easily replaced with a fresh, adherent backing. And, if the study
ePatch Revolutionizes Continuous ECG Data Collection in Clinical Trials
participant is experiencing skin irrita-tion, unlike all other cardiac patches, the ePatch is easily converted to a small
electrode format, allowing the irritated skin to breathe. In both cases, the re-cording session continues, successfully completing the study’s data set.
BioTel Research is a highly experi-enced and dedicated global core lab that has completed thousands of clin-ical trials and provisioned tens of thou-sands of investigative sites worldwide. As part of the world’s leading remote monitoring company, BioTelemetry, Inc. (Nasdaq: BEAT), BioTel Research com-bines cardiac safety testing and med-ical imaging for the advancement of biopharmaceutical development.
For more information about using ePatch in your next cardiac safety study, please visit gobio.com/epatch-studies, or contact us at +1.301.214.7628 or [email protected]. The can-do staff at BioTel Research will be happy to as-sist you.
Company InformationCompany Name: _____________________________________________________________Contact: ____________________________________ Title: _________________Street: _____________________________________________________________City: ____________________________________ State: ________ Zip: __________Phone: ________________________ E-mail: ____________________________________Accounts Payable E-mail: ____________________________________
Ad Agency Information (if applicable)Agency: ____________________________________ Contact: ________________________________ Street: _____________________________________________________________City: ____________________________________ State: ________ Zip: __________Phone: ________________________ E-mail: ____________________________________
Space ReservationsDisplay ad (1/4 page or larger):Ad Size:_______________ Number of Issues:_______________ Total Cost:__________________
Product Showcase Listings:Number of Placements:_______________ Total Cost:_______________
Total Amount Due: ____________Payment Method: Bill Me Now Bill Me Upon Publication Credit Card
Charge InformationCredit Cards Accepted: Visa, Mastercard, American Express or Discover
Account #: ____________________________ Expiration Date: ___________Billing address zip code: ___________ CSV/CVV Code: ___________
___________________________________________Signature
___________________________________________
Cancellation Policy: Onsite issue advertisers can-celling after March 1, 2020, will be billed for 50% of the total net cost. Advertisers cancelling after May 15, 2020, will be billed for 100% of the total net cost.
Please return to Jenn Waters, CustomNEWS:
[email protected] Fax Number.
Questions? 240/401-6779
DIA 2020 Show Daily Advertising
Insertion Order
SHOW DAILY
9:00am–12:30pm Half Day Morning Preconference Short Courses*
9:00am–5:00pm Full Day Preconference Short Courses*
1:30–5:00pm
Half Day Afternoon Preconference Short Courses*
2:30–5:00pm
Professional Development Sessions
Sunday
Issue OneJune 23, 2019
*Space is limited for Preconference Short Courses. Onsite Registration is available, but not guaranteed.
Welcome to San Diego!
®
IWRS/RTMS|CTMS| Safety|ePRO/eCOA|AE/SAE|Imaging|Reporting
EDC|DM|IWRS|CTMS
Focus on your study,not your bottom line.
Visit Axiom for coffee at #2531. Reach us at www.axiommetrics.com or [email protected].
Fixed cost model. No change orders. Invest to save.
ModuleseClinical Suite
Better Decisions
Short Timelines
Unmatched Service
Unified Technology
Unified eClinical Solution.
Up Close and PersonalGet to know your fellow DIA members with Member Spotlights in each Show Daily. Today’s issue features: • Jonathan Andrus• Stella Blackburn• Linda Bowen• Gerald Dal Pan• Munish Mehra
Professor Gui-do Rasi began his second term as Ex-ecutive Director of the European Medicines Agency (EMA) on Novem-ber 16, 2015. From November 2014 to mid-November 2015, Professor Rasi served as EMA’s Principal Adviser in Charge of Strategy.
From November 2011 to November 2014 he was the Executive Director of EMA and a member of its Management Board in the three years prior.
Dr. Joanne Waldstreicher has oversight across John-son & Johnson pharmaceuti-cals, devices, and consumer products for safety, epide-miology, clin-ical and reg-ulatory operations transformation, collaborations on ethical science, and technology and R&D policies, including those related to clinical trial transpar-ency and compassionate access.
Meet your DIA 2019 Honorary Co-Chairs
Joanne Waldstreicher, MDChief Medical OfficerJohnson & Johnson
Professor Guido Rasi, MDExecutive Director, European Medicines AgencyEuropean Union
![CALS/EC実証実験現場の紹介...Y)...:) [] ()... CALS:)](https://img.dokumen.tips/doc/110x75/5f911b508043ba271f7c7f2a/-calseceecc-y-cals-.jpg)
